Neuralink, the brain-computer interface company founded by Elon Musk in 2016, announced at the May 2026 Society for Neuroscience meeting that its PRIME (Precise Robotically IMplanted Brain-Computer InterfacE) Study has enrolled and implanted the N1 BCI device in six patients, up from the initial patient Noland Arbaugh implanted in January 2024. All six participants, who have quadriplegia due to spinal cord injury or amyotrophic lateral sclerosis, have demonstrated durable motor intention decoding, with the earliest implant now functioning reliably for 18 months.

Noland Arbaugh achieved consistent cursor control at 8 bits per second, a speed that enables practical computer use including web browsing, messaging, and playing turn-based strategy games entirely via thought.

The N1 device consists of 1,024 flexible electrode threads, each thinner than a human hair, implanted into the brain's motor cortex by the R1 surgical robot. The threads sample the electrical activity of individual neurons, and machine learning algorithms decode the neural firing patterns into intended movements. Neuralink has iterated on the implant hardware based on experience with the first cohort: a revised connector design between the electrode arrays and the sealed, inductively charged implant body has eliminated the thread retraction issue observed in Arbaugh's implant within the first month, and a redesigned signal-processing ASIC delivers 24-bit resolution at 30 kHz per channel, up from 10-bit resolution in the original configuration.

The company is in discussions with the FDA to expand the PRIME Study to 30 patients and to add a study arm testing the N1 in patients with communication disorders resulting from locked-in syndrome.

📋 Synchron's Less-Invasive Approach

Synchron, founded in 2012 and based in New York with engineering in Melbourne, Australia, has taken a fundamentally different approach to BCI surgery. Its Stentrode device is a self-expanding stent-like electrode array that is delivered through the jugular vein in the neck and positioned in a blood vessel adjacent to the brain's motor cortex, entirely avoiding open brain surgery. The device records local field potentials from the brain through the blood vessel wall, which are less detailed than single-neuron recordings but sufficient for decoding motor intention.

The signals are transmitted to a receiver implanted in the chest, which communicates wirelessly with external devices.

The less invasive nature of the Stentrode has enabled Synchron to scale more rapidly. The company's COMMAND study enrolled 6 patients in the US with severe paralysis, showing that all could control a computer cursor with 92% accuracy on a motor imagery task after training, and 4 of 6 achieved functional digital device control. Synchron received regulatory approval in Australia in 2024 and Japan in early 2026, and its CE marking application is under review by the European Medicines Agency.

The device is now commercially available in Australia for patients with severe paralysis, making it the first BCI available through routine clinical care rather than only in clinical trials.

🔮 Speech Decoding and Sensory Feedback: The Next Frontier

The BrainGate consortium, a multi-institutional academic research group led by Brown University, Massachusetts General Hospital, Stanford University, and the Providence VA Medical Center, continues to push the boundaries of what BCIs can achieve. At the 2026 Society for Neuroscience meeting, BrainGate researchers demonstrated a speech BCI decoding attempted speech from a participant with ALS at 62 words per minute with a 125,000-word vocabulary and a word error rate of 23.8%, approaching the conversational speech rate of approximately 160 words per minute.

A separate BrainGate participant was able to control a robotic prosthetic limb with sufficient dexterity to grasp and manipulate objects, and for the first time, a bidirectional BCI provided intracortical microstimulation feedback that the participant perceived as tactile sensations from the prosthetic limb's fingertips.

In May 2026, the FDA issued a landmark guidance document, "Implanted Brain-Computer Interface Devices for Patients with Paralysis or Amputation," which establishes a clearer regulatory pathway for BCI devices as Class III medical devices requiring premarket approval. The guidance specifies recommended clinical trial endpoints (motor decoding throughput, communication rate, and functional independence measures), safety monitoring requirements for long-term neural tissue response, and cybersecurity requirements for wireless data transmission.

The guidance is expected to accelerate the BCI field from academic research toward commercial medical devices capable of restoring function to millions of people living with paralysis.